The FDA Breakthrough Device Designation is a significant regulatory milestone that can substantially shorten the development and review timeline for new medical devices. For Better Therapeutics, this could mean faster market access for its digital therapeutic platform, which is crucial in a competitive healthcare market. The designation not only validates the potential of the platform but also could attract investor interest, potentially positively impacting the stock price in the short term.